This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Woody, R. C. Articles by Leech, R. W. Search for Related Content PubMed PubMed Citation Articles by Woody, R. C. Articles by Leech, R. W. Social Bookmarking                   What's this?

Absence of β-Amyloid Immunoreactivity in Mesial Temporal Lobe in Cockayne's Syndrome

Departments of Pediatrics, Neurology and Psychiatry University of Maryland at Baltimore, Baltimore, MD

Brian N. Harding, DPhil, BM, MRCPath

Department of Neuropathology, Hospitals for Sick Children, London, United Kingdom

Roger A. Brumback, MD

Department of Pathology, University of Oklahoma College of Medicine, Oklahoma City, OK

Richard W. Leech, MD

Department of Pathology, University of Oklahoma College of Medicine, Oklahoma City, OK

Cockayne's syndrome is associated with dementia and other physical signs of premature senescence. Death usually occurs in the first or second decade of life. Because previous neuropathologic descriptions have included neurofibrillary tangles and calcific and dystrophic cerebrovascular changes, we examined the mesial temporal lobes of three children with Cockayne's syndrome (confirmed by 254-nm ultraviolet light studies). Immunohistochemistry was used to determine if β-amyloid immunoreactivity was present in the parenchyma or cerebral blood vessels. Tissues from the mesial temporal lobe of patients with Alzheimer's disease and Down syndrome were used as controls. None of the three temporal lobes from patients with Cockayne's syndrome contained β-amyloid immunoreactive material in either the parenchyma or vessels; all of the Alzheimer's disease and Down syndrome controls had β-amyloid immunoreactivity. (J Child Neurol 1991;6:32-34).

Journal of Child Neurology, Vol. 6, No. 1, 32-34 (1991)
DOI: 10.1177/088307389100600106


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?